Antibiotic-Nigella Sativa Fusion (ANF) as a novel approach intended for the treatment against bacteria forming biofilm in osteomyelitis
Multi-drug resistant bacteria are one of the global problems facing humanity. One of the bacteria of concern causing osteomylitis is Staphylococcus aureus. Biofilm from this bacterium in the infected bones has been clinically isolated from the infected patients. A novel formulation of a contempora...
Saved in:
Main Authors: | , , , , , , |
---|---|
Format: | Conference or Workshop Item |
Language: | English |
Published: |
2015
|
Subjects: | |
Online Access: | http://irep.iium.edu.my/48736/1/48376.pdf http://irep.iium.edu.my/48736/ http://eurobiofilms2015.ics.dk/ |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Multi-drug resistant bacteria are one of the global problems facing humanity. One of the bacteria of concern
causing osteomylitis is Staphylococcus aureus. Biofilm from this bacterium in the infected bones has been
clinically isolated from the infected patients. A novel formulation of a contemporary antibiotic i.e
Gentamicin (an Aminoglycoside) was fused with prophetic medicine i.e Nigella Sativa oil (NSO) (also
known as black seed oil) and thereafter characterised. The fusion was done by preparing the emulsions of the
two materials with the aid of varying amount of surfactants. Compatibility testing of the two compositions
was also conducted pre and post fusion and pre and post gamma irradiation by Fourier-Transform Infra Red
(FTIR), HPLC and Thin Layer Chromatography (TLC). In-vitro efficacy test of the fusion was further tested
against both the sensitive and the resistant of the commercial and the clinically isolated S.Aureus. Cell
viability was also performed on osteoclast cells to determine preliminary safety profile of the fusion. Results
indicate that the fusions are physically and chemically compatible and stable with significantly higher safety
level than gentamicin alone. The fusions showed ability to inhibit biofilm formation and are also more
effective in-vitro particularly against the resistant S.Aureus unlike Gentamicin. With further clinical proofs,
the findings could have high impact on current treatment regimen against multi-drug resistant bacteria
particularly for osteomyelitis. It is also pave the way for more antibiotics to be fused with NSO and perhaps
other prophetic medicine and tested for the same purpose or others. |
---|